Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer
- Conditions
- SurgeryMetastasisPancreatic CancerImmunosuppression
- Interventions
- Registration Number
- NCT05810792
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Brief Summary
A key aspect of the trial is that functions of anti-neoplastic T cells and natural killer (NK) cells, may be inhibited by immunosuppressive signals from myeloid cells, in particular reactive oxygen species (ROS) produced by several subsets of myeloid cells. In cancer, such immunosuppressive cells are commonly denoted myeloid-derived suppressor cells (MDSCs), which are immature monocytes and granulocytes that impede immune-mediated clearance of malignant cells by multiple mechanisms, including the formation of immunosuppressive ROS via myeloid cell NADPH oxidase (NOX2). The presence of MDSCs within or adjacent to tumor tissue is assumed to facilitate the growth and spread of tumors and may also dampen the efficacy of cancer immunotherapies. The underlying hypothesis for this clinical trial is the administration of HDC/IL-2 will reduce surgery-induced inflammation and reduce metastasis. A phase I/II open label, single-center study of the safety, tolerability, and efficacy of peri- and postoperative therapy with histamine dihydrochloride and low-dose interleukin-2 treatment in subjects with primary pancreatic cancer.To assess the frequency and extent of adverse events associated with low dose interleukin-2 and histamine dihydrochloride when used as perioperative therapy.To determine progression free survival and overall survival following surgery, and compare with matched historical controls from the Swedish Cancer Registry.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 50
- Subjects must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution.
- Subject is a male or female age >18
- By the surgeon´s evaluation fit for pancreatic surgery
- Subjects must have radiologic, and or cytologic confirmation of primary pancreatic cancer
Exclusion Criteria (any of the following):
- Class III or IV cardiac disease, hypotension or severe hypertension, vasomotor instability, serious or uncontrolled cardiac dysrhythmias (including ventricular arrhythmias) at any time, acute myocardial infarction within the past 6 months, active uncontrolled angina pectoris or symptomatic arteriosclerotic peripheral blood vessel disease.
- History of uncontrolled seizures, severe central nervous system disorders, or psychiatric disability thought to be clinically significant in the opinion of the Investigator and adversely affecting compliance to protocol.
- Any other condition or symptoms preventing the patient from entering the study, according to the PI's judgement.
- A woman of childbearing potential (WOCBP) must agree to comply with using an effective contraceptive method for the duration of the treatment (a WOCBP is a sexually mature woman who is not surgically sterile or has not been naturally postmenopausal for at least 12 consecutive months). Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly. Local laws and regulations may require use of alternative and/or additional contraception methods. One of the highly effective methods of contraception listed below is required during study duration and until the end of relevant systemic exposure, defined as 5 months after the end of study treatment.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Patients receiving immunomodulating treatment Histamine Dihydrochloride (HDC) - Patients receiving immunomodulating treatment Interleukin-2 (IL-2) -
- Primary Outcome Measures
Name Time Method Incidence and severity of Treatment-Emergent Adverse Events as assessed by NCI-CTCAE When the first 14 patients have undergone one full 3-week cycle with HDC/IL-2 (approximately 18 months after trial start) Incidence and severity grade of adverse events occuring during and after treatment will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.
- Secondary Outcome Measures
Name Time Method Overall survival 24 months Comparing matched historical controls from national registry
Disease free survival 24 months Comparing matched historical controls from national registry
Changes in T cell subsets in blood Change from pre-surgical levels to levels during the post-surgical week Changes in T cell number and expression of activation markers during surgery
Changes in Myeloid cell populations Change from pre-surgical levels to levels during the post-surgical week Changes in myeloid cell number and markers of activation and inhibition
Tumor infiltrating lymphocytes and tumor infiltrating myeloid cells immediately after the surgery Tumor pieces removed during surgery will be assessed for immune populations
Carbohydrate antigen 19-9 12 months Serum CA 19-9 levels are monitored as a biomarker for disease recurrance
Changes in Natural killer cell subsets in blood Change from pre-surgical levels to levels during the post-surgical week Changes in NK cell number and expression of activation markers during surgery